Drugs / LY2963016
LY2963016
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02955953 | Nov 2016 → Jan 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01688635 | Sep 2012 → Feb 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01634165 | Jul → Sep 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01600950 | May → Jul 2012 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01476345 | Nov 2011 → Jul 2012 | diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01374178 | Jun → Jul 2011 | diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT03338023 | Mar 2018 → Mar 2020 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03338010 | Mar 2018 → Mar 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02302716 | Dec 2014 → Jul 2016 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01421459 | Sep 2011 → Sep 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01421147 | Aug 2011 → Aug 2012 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2963016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01421459 ↗ |
| Known as | Basaglar | “Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence...” PMID 31119716 ↗ Aug 2019 |
| Known as | insulin glargine | “INTRODUCTION: LY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus® insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product...” PMID 35471721 ↗ Apr 20221“INTRODUCTION: LY2963016 insulin glargine (LY IGlar) and Lantus® (IGlar), both with identical primary amino acid sequences, were compared in two phase 3 studies for intrapatient...” PMID 29855972 ↗ May 2018 |
| Known as | Lilly insulin glargine | “Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence...” PMID 31119716 ↗ Aug 2019 |
| Known as | LY IGlar | “INTRODUCTION: LY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus® insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product...” PMID 35471721 ↗ Apr 20222“Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence...” PMID 31119716 ↗ Aug 2019 “INTRODUCTION: LY2963016 insulin glargine (LY IGlar) and Lantus® (IGlar), both with identical primary amino acid sequences, were compared in two phase 3 studies for intrapatient...” PMID 29855972 ↗ May 2018 |
| Modality | Protein / enzyme biologic | “both with identical primary amino acid sequences” PMID 29855972 ↗ May 2018 |
| Route | Subcutaneous | “Administered subcutaneously” NCT01374178 ↗ |